SNX 5422

Drug Profile

SNX 5422

Alternative Names: 113; PF-04929113; PF-113; PF-4929113; SNX-5422

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Serenex
  • Developer Esanex; Serenex
  • Class Amides; Antineoplastics; Indazoles; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I Chronic lymphocytic leukaemia; Haematological malignancies; Neuroendocrine tumours; Solid tumours
  • No development reported Lung cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Feb 2017 Esanex initiates enrolment in a phase I trial for Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (NCT02973399)
  • 02 Feb 2017 Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (PO) (NCT02914327)
  • 22 Nov 2016 Esanex plans a phase I trial for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO, Capsule) (NCT02973399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top